The Experts below are selected from a list of 552 Experts worldwide ranked by ideXlab platform

Danielle Larouche - One of the best experts on this subject based on the ideXlab platform.

  • 27.12 MHz Radiofrequency Ablation for Benign Cutaneous Lesions
    BioMed research international, 2016
    Co-Authors: Dong Hyun Kim, Dong Ju Hyun, Raymonde Piquette, Clément Beaumont, Lucie Germain, Danielle Larouche
    Abstract:

    As surgical and/or ablative modalities, radiofrequency (RF) has been known to produce good clinical outcomes in dermatology. Recently, 27.12 MHz RF has been introduced and has several advantages over conventional 4 or 6 MHz in terms of the precise ablation and lesser pain perception. We aimed to evaluate the clinical efficacy and safety of 27.12 MHz RF for the treatment of benign cutaneous lesions. Twenty female patient subjects were enrolled. Digital photography and a USB microscope camera were used to monitor the clinical results before one session of treatment with 27.12 MHz RF and after 1 and 3 weeks. Treated lesions included telangiectasias, cherry and spider angiomas, skin tags, seborrheic keratoses, lentigo, milium, Dilated Pore, acne, piercing hole, and one case of neurofibroma. For vascular lesions, clinical results were excellent for 33.3%, good for 44.4%, moderate for 11.1%, and poor for 11.1%. For nonvascular lesions (epidermal lesions and other benign cutaneous lesions), clinical results were excellent for 48.3%, good for 45.2%, moderate for 3.2%, and poor for 3.2%. No serious adverse events were observed. Mild adverse events reported were slight erythema, scale, and crust. The 27.12 MHz RF treatment of benign vascular and nonvascular lesions appears safe and effective after 3 weeks of follow-up.

  • 27.12 MHz Radiofrequency Ablation for Benign Cutaneous Lesions
    Hindawi Limited, 2016
    Co-Authors: Dong Hyun Kim, Dong Ju Hyun, Raymonde Piquette, Clément Beaumont, Lucie Germain, Danielle Larouche
    Abstract:

    As surgical and/or ablative modalities, radiofrequency (RF) has been known to produce good clinical outcomes in dermatology. Recently, 27.12 MHz RF has been introduced and has several advantages over conventional 4 or 6 MHz in terms of the precise ablation and lesser pain perception. We aimed to evaluate the clinical efficacy and safety of 27.12 MHz RF for the treatment of benign cutaneous lesions. Twenty female patient subjects were enrolled. Digital photography and a USB microscope camera were used to monitor the clinical results before one session of treatment with 27.12 MHz RF and after 1 and 3 weeks. Treated lesions included telangiectasias, cherry and spider angiomas, skin tags, seborrheic keratoses, lentigo, milium, Dilated Pore, acne, piercing hole, and one case of neurofibroma. For vascular lesions, clinical results were excellent for 33.3%, good for 44.4%, moderate for 11.1%, and poor for 11.1%. For nonvascular lesions (epidermal lesions and other benign cutaneous lesions), clinical results were excellent for 48.3%, good for 45.2%, moderate for 3.2%, and poor for 3.2%. No serious adverse events were observed. Mild adverse events reported were slight erythema, scale, and crust. The 27.12 MHz RF treatment of benign vascular and nonvascular lesions appears safe and effective after 3 weeks of follow-up

Dong Hyun Kim - One of the best experts on this subject based on the ideXlab platform.

  • 27.12 MHz Radiofrequency Ablation for Benign Cutaneous Lesions
    BioMed research international, 2016
    Co-Authors: Dong Hyun Kim, Dong Ju Hyun, Raymonde Piquette, Clément Beaumont, Lucie Germain, Danielle Larouche
    Abstract:

    As surgical and/or ablative modalities, radiofrequency (RF) has been known to produce good clinical outcomes in dermatology. Recently, 27.12 MHz RF has been introduced and has several advantages over conventional 4 or 6 MHz in terms of the precise ablation and lesser pain perception. We aimed to evaluate the clinical efficacy and safety of 27.12 MHz RF for the treatment of benign cutaneous lesions. Twenty female patient subjects were enrolled. Digital photography and a USB microscope camera were used to monitor the clinical results before one session of treatment with 27.12 MHz RF and after 1 and 3 weeks. Treated lesions included telangiectasias, cherry and spider angiomas, skin tags, seborrheic keratoses, lentigo, milium, Dilated Pore, acne, piercing hole, and one case of neurofibroma. For vascular lesions, clinical results were excellent for 33.3%, good for 44.4%, moderate for 11.1%, and poor for 11.1%. For nonvascular lesions (epidermal lesions and other benign cutaneous lesions), clinical results were excellent for 48.3%, good for 45.2%, moderate for 3.2%, and poor for 3.2%. No serious adverse events were observed. Mild adverse events reported were slight erythema, scale, and crust. The 27.12 MHz RF treatment of benign vascular and nonvascular lesions appears safe and effective after 3 weeks of follow-up.

  • 27.12 MHz Radiofrequency Ablation for Benign Cutaneous Lesions
    Hindawi Limited, 2016
    Co-Authors: Dong Hyun Kim, Dong Ju Hyun, Raymonde Piquette, Clément Beaumont, Lucie Germain, Danielle Larouche
    Abstract:

    As surgical and/or ablative modalities, radiofrequency (RF) has been known to produce good clinical outcomes in dermatology. Recently, 27.12 MHz RF has been introduced and has several advantages over conventional 4 or 6 MHz in terms of the precise ablation and lesser pain perception. We aimed to evaluate the clinical efficacy and safety of 27.12 MHz RF for the treatment of benign cutaneous lesions. Twenty female patient subjects were enrolled. Digital photography and a USB microscope camera were used to monitor the clinical results before one session of treatment with 27.12 MHz RF and after 1 and 3 weeks. Treated lesions included telangiectasias, cherry and spider angiomas, skin tags, seborrheic keratoses, lentigo, milium, Dilated Pore, acne, piercing hole, and one case of neurofibroma. For vascular lesions, clinical results were excellent for 33.3%, good for 44.4%, moderate for 11.1%, and poor for 11.1%. For nonvascular lesions (epidermal lesions and other benign cutaneous lesions), clinical results were excellent for 48.3%, good for 45.2%, moderate for 3.2%, and poor for 3.2%. No serious adverse events were observed. Mild adverse events reported were slight erythema, scale, and crust. The 27.12 MHz RF treatment of benign vascular and nonvascular lesions appears safe and effective after 3 weeks of follow-up

Kwangjoong Kim - One of the best experts on this subject based on the ideXlab platform.

  • a case of pilar sheath acanthoma which originated from outer root sheath
    Journal of Clinical Dermatology, 2008
    Co-Authors: Suckjoon Jung, Nareu Seung, Youngju Seo, Eunju Park, Chul Woo Kim, Hee Jin Cho, Kwang Ho Kim, Kwangjoong Kim
    Abstract:

    Pilar sheath acanthoma is a rare, benign follicular hamartoma commonly affecting middle-aged and elderly individuals. It is characterized by a small, solitary, skin-colored papule situated on the head and neck, particularly around the upper lip. The lesion shares some features with trichofolliculoma and Dilated Pore of Winer, so it should be differentiated from these. Cytokeratin (CK) is a useful marker for studying the origin of epithelial tumors. We report a case of pilar sheath acanthoma which originated from outer root sheath using CK. (Korean J Dermatol 2008;46(7):955∼957)

Yoshiaki Hori - One of the best experts on this subject based on the ideXlab platform.

  • hair cortex comedo
    American Journal of Dermatopathology, 1996
    Co-Authors: Akito Toshitani, Shuhei Imayama, Atsumichi Urabe, Hiromaro Kiryu, Yoshiaki Hori
    Abstract:

    We report two cases of skin lesions that clinically resemble a comedo. Both lesions demonstrated a firm black papule which was histopathologically reminiscent of a Dilated hair follicle associated with an abnormality of the hair cortex. These findings are thus considered to represent a unique and peculiar variant of the Dilated Pore of Winer, and the term "hair cortex comedo" is therefore believed to be suitable for such lesions.

Dong Ju Hyun - One of the best experts on this subject based on the ideXlab platform.

  • 27.12 MHz Radiofrequency Ablation for Benign Cutaneous Lesions
    BioMed research international, 2016
    Co-Authors: Dong Hyun Kim, Dong Ju Hyun, Raymonde Piquette, Clément Beaumont, Lucie Germain, Danielle Larouche
    Abstract:

    As surgical and/or ablative modalities, radiofrequency (RF) has been known to produce good clinical outcomes in dermatology. Recently, 27.12 MHz RF has been introduced and has several advantages over conventional 4 or 6 MHz in terms of the precise ablation and lesser pain perception. We aimed to evaluate the clinical efficacy and safety of 27.12 MHz RF for the treatment of benign cutaneous lesions. Twenty female patient subjects were enrolled. Digital photography and a USB microscope camera were used to monitor the clinical results before one session of treatment with 27.12 MHz RF and after 1 and 3 weeks. Treated lesions included telangiectasias, cherry and spider angiomas, skin tags, seborrheic keratoses, lentigo, milium, Dilated Pore, acne, piercing hole, and one case of neurofibroma. For vascular lesions, clinical results were excellent for 33.3%, good for 44.4%, moderate for 11.1%, and poor for 11.1%. For nonvascular lesions (epidermal lesions and other benign cutaneous lesions), clinical results were excellent for 48.3%, good for 45.2%, moderate for 3.2%, and poor for 3.2%. No serious adverse events were observed. Mild adverse events reported were slight erythema, scale, and crust. The 27.12 MHz RF treatment of benign vascular and nonvascular lesions appears safe and effective after 3 weeks of follow-up.

  • 27.12 MHz Radiofrequency Ablation for Benign Cutaneous Lesions
    Hindawi Limited, 2016
    Co-Authors: Dong Hyun Kim, Dong Ju Hyun, Raymonde Piquette, Clément Beaumont, Lucie Germain, Danielle Larouche
    Abstract:

    As surgical and/or ablative modalities, radiofrequency (RF) has been known to produce good clinical outcomes in dermatology. Recently, 27.12 MHz RF has been introduced and has several advantages over conventional 4 or 6 MHz in terms of the precise ablation and lesser pain perception. We aimed to evaluate the clinical efficacy and safety of 27.12 MHz RF for the treatment of benign cutaneous lesions. Twenty female patient subjects were enrolled. Digital photography and a USB microscope camera were used to monitor the clinical results before one session of treatment with 27.12 MHz RF and after 1 and 3 weeks. Treated lesions included telangiectasias, cherry and spider angiomas, skin tags, seborrheic keratoses, lentigo, milium, Dilated Pore, acne, piercing hole, and one case of neurofibroma. For vascular lesions, clinical results were excellent for 33.3%, good for 44.4%, moderate for 11.1%, and poor for 11.1%. For nonvascular lesions (epidermal lesions and other benign cutaneous lesions), clinical results were excellent for 48.3%, good for 45.2%, moderate for 3.2%, and poor for 3.2%. No serious adverse events were observed. Mild adverse events reported were slight erythema, scale, and crust. The 27.12 MHz RF treatment of benign vascular and nonvascular lesions appears safe and effective after 3 weeks of follow-up